Literature DB >> 11686544

Hypopituitarism in langerhans cell histiocytosis: seven cases and literature review.

D Modan-Moses1, M Weintraub, J Meyerovitch, G Segal-Lieberman, B Bielora.   

Abstract

Central nervous system (CNS) involvement and, in particular, hypothalamic-pituitary involvement are well described features of Langerhans cell histiocytosis (LCH). The actual incidence of CNS-LCH disease is unknown and the natural history is poorly understood. Diabetes insipidus (DI) is reported to be the most common and well described manifestation of hypothalamic-pituitary involvement (up to 50%). Anterior pituitary dysfunction has been reported in up to 20% of patients with LCH, and occurs almost exclusively concurrently with DI. In the current paper we describe our experience with 7 patients (6 females and 1 male) in whom hypothalamicpituitary involvement was a major feature of LCH. Diagnosis was made in 4 patients during childhood or adolescence, and 3 patients were over 18 years old at the time of diagnosis. Our series exemplifies the wide spectrum of LCH-induced hypopituitarism, and demonstrates some unique features, including a higher incidence of CRH/ACTH deficiency compared to other reports (4/7 patients), and massive obesity in 2 of our patients. Endocrine function was not improved in any of our patients following medical treatment of LCH with chemotherapy and glucocorticoids. We conclude that pituitary-hypothalamic dysfunction is a common feature of LCH, and therefore all LCH patients should undergo a thorough endocrine evaluation periodically.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11686544     DOI: 10.1007/bf03343902

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  24 in total

Review 1.  Current therapy for Langerhans cell histiocytosis.

Authors:  V Broadbent; H Gadner
Journal:  Hematol Oncol Clin North Am       Date:  1998-04       Impact factor: 3.722

Review 2.  The epidemiology of Langerhans cell histiocytosis.

Authors:  H S Nicholson; R M Egeler; M E Nesbit
Journal:  Hematol Oncol Clin North Am       Date:  1998-04       Impact factor: 3.722

Review 3.  Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society.

Authors:  B E Favara; A C Feller; M Pauli; E S Jaffe; L M Weiss; M Arico; P Bucsky; R M Egeler; G Elinder; H Gadner; M Gresik; J I Henter; S Imashuku; G Janka-Schaub; R Jaffe; S Ladisch; C Nezelof; J Pritchard
Journal:  Med Pediatr Oncol       Date:  1997-09

Review 4.  Report of the Histiocyte Society workshop on "Central nervous system (CNS) disease in Langerhans cell histiocytosis (LCH)".

Authors: 
Journal:  Med Pediatr Oncol       Date:  1997-08

5.  Histiocytosis X in the optic chiasm of an adult with hypopituitarism. Case report.

Authors:  E A Smolik; M Devecerski; J S Nelson; K R Smith
Journal:  J Neurosurg       Date:  1968-09       Impact factor: 5.115

Review 6.  Diabetes insipidus secondary to Langerhans' cell histiocytosis: is radiation therapy indicated?

Authors:  K E Rosenzweig; R J Arceci; N J Tarbell
Journal:  Med Pediatr Oncol       Date:  1997-07

7.  Primary hypothyroidism, central diabetes insipidus and growth hormone deficiency in multisystem Langerhans cell histiocytosis: a case report.

Authors:  B Rami; U Schneider; K Wandl-Vergesslich; H Frisch; E Schober
Journal:  Acta Paediatr       Date:  1998-01       Impact factor: 2.299

8.  Thyroid involvement by malignant histiocytosis of Langerhans' cell type.

Authors:  S Kitahama; M Iitaka; T Shimizu; N Serizawa; N Fukasawa; S Miura; S Kawasaki; K Yamanaka; Y Kawakami; S Murakami; J Ishii; S Katayama
Journal:  Clin Endocrinol (Oxf)       Date:  1996-09       Impact factor: 3.478

9.  A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group.

Authors: 
Journal:  Arch Dis Child       Date:  1996-07       Impact factor: 3.791

10.  Langerhans cell (eosinophilic) granulomatosis. A clinicopathologic study encompassing 50 years.

Authors:  P H Lieberman; C R Jones; R M Steinman; R A Erlandson; J Smith; T Gee; A Huvos; P Garin-Chesa; D A Filippa; C Urmacher; M D Gangi; M Sperber
Journal:  Am J Surg Pathol       Date:  1996-05       Impact factor: 6.394

View more
  5 in total

1.  Analysis of 43 cases of Langerhans cell histiocytosis (LCH)-induced central diabetes insipidus registered in the JLSG-96 and JLSG-02 studies in Japan.

Authors:  Yoko Shioda; Souichi Adachi; Shinsaku Imashuku; Kazuko Kudo; Toshihiko Imamura; Akira Morimoto
Journal:  Int J Hematol       Date:  2011-11-17       Impact factor: 2.490

2.  Treatment of patients with hypothalamic-pituitary lesions as adult-onset Langerhans cell histiocytosis.

Authors:  Shinsaku Imashuku; Naoko Kudo; Shigehiro Kaneda; Hiroshi Kuroda; Tsuguka Shiwa; Tetsuya Hiraiwa; Atsushi Inagaki; Akira Morimoto
Journal:  Int J Hematol       Date:  2011-10-21       Impact factor: 2.490

3.  Manifestation of a sellar hemangioblastoma due to pituitary apoplexy: a case report.

Authors:  Ralph T Schär; Istvan Vajtai; Rahel Sahli; Rolf W Seiler
Journal:  J Med Case Rep       Date:  2011-10-04

Review 4.  [Hypophyseal coma].

Authors:  B L Herrmann; K Mann
Journal:  Internist (Berl)       Date:  2003-10       Impact factor: 0.743

5.  The pituitary gland in patients with Langerhans cell histiocytosis: a clinical and radiological evaluation.

Authors:  Neslihan Kurtulmus; Meral Mert; Refik Tanakol; Sema Yarman
Journal:  Endocrine       Date:  2014-09-11       Impact factor: 3.633

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.